Among the assorted communities of brain cells contained within an 8 millimeter punch of cortex, scientists have captured what might reflect two pivotal microglial moments along the decades-long ...

A blood test may be almost as good as a brain scan for determining where someone lies along the Alzheimer’s disease continuum. So conclude scientists led by Gemma Salvadó and Oskar Hansson at Lund ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

Proteomic panels come up short in the search for a plasma biomarker of Lewy bodies. AI may help.

Clinicians have started using blood tests of p-tau217, a marker of amyloid plaques, to help diagnose AD in routine patient care, not just research studies. Alas, at AD/PD 2026, held March 17-21 in ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Past AlzForum Coverage: Human Amyloid Imaging 2013 Solanezumab Selected for Alzheimer’s A4 Prevention Trial HAI—Spotlight on Tau Tracers at Human Amyloid Imaging Meeting HAI—Amyloid Imaging in the ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

When cells are starved or distressed, RNA and RNA-binding proteins can coalesce into membraneless liquid droplets called stress granules. These shut down translation, helping cells conserve energy.

Summary These transgenic mice express a chimeric mouse/human APP carrying the Swedish mutation under the control of the mouse prion protein promoter. This line, C3-3, was generated in parallel with ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...